Prevalence and factors associated with suicide attempts among Moroccan patients with schizophrenia: cross-sectional study.

Suicide is an important cause of death among patients affected by schizophrenia. The lifetime prevalence is 10-15%. The identification of factors associated with suicide attempts will help to identify preventive and therapeutic strategies to reduce the toll of suicide. Aims: The purpose of this study is to investigate the prevalence of suicide attempts and their sociodemographic and clinical characteristics in Moroccan patients with schizophrenia. Materials and methods: This is a cross-sectional study of patients admitted to our Hospital of Psychiatry in Morocco, between year and year, with adiagnosis f schizophrenia. Results: In our sample (n=304), 65 (21.4%) had attempted suicide. Suicide attempts were significantly and positively associated with a family history of bipolar disorder, comorbidity with a substance use disorder, a relatively short duration of treatment, poor adherence to medication, and severe general, positive, and depressive symptoms. Conclusion: The prevention of suicide risk requires the effective management of depressive and addictive comorbidities, the reduction of schizophrenia symptoms through appropriate treatment and an effort to improve adherence.

Prevalence of and Risk Factors for Suicide Attempts Among Patients With Severe Psychiatric Disorders in Eastern Morocco.

Background: Suicide attempts are common in patients with severe psychiatric disorders; however, they are rarely studied in this population. Aims: To investigate the prevalence and risk factors associated with suicide attempts among patients with severe psychiatric disorders. Method: This is a cross-sectional study of patients admitted to the Mohammed VI University Hospital of Psychiatry in Oujda, Morocco. Results: A total of 250 patients with a psychiatric disorder were recruited in this study. Among these, 78 cases (31.2%) had a personal history of suicide attempts. A personal history of suicide attempt was significantly higher among women compared to men (45.5% vs. 27.2%, p = .0099). The most common method of suicide attempts was jumping from heights (31%). Patients with a personal history of suicide attempts had a significantly higher prevalence of alcohol consumption (p = .0063), family history of psychiatric disorders (p = .002), family history of suicide attempt (p = .00004), and family history of suicide (p = .018) compared to those who had never made suicide attempts. Limitations: As suicidal behavior is highly stigmatized in Morocco, the number of patients who have made a suicide attempt may be underestimated. Conclusion: Our findings justify the need to provide specialized support to psychiatric patients with risk factors for suicide attempts.

A very rare case of priapism under aripiprazole in a patient followed for bipolar disorder: A CARE-compliant report.

INTRODUCTION AND IMPORTANCE: Priapism is a urological emergency characterized by abnormally prolonged, painful and irreducible erection. It occurs without a sexual stimulation and habitually exceeds 6 h. About a half of iatrogenic priapisms are believed to be associated with antipsychotics. Until to date, very few cases of aripiprazole-associated priapism were reported. CASE PRESENTATION: In this case report, we present the clinical findings of a 40-year-old patient that developed priapism after treatment with aripiprazole after his hospitalization for an episode of clinical mania following treatment discontinuation for bipolar I disorder. The management was successful and priapism was resolved spontaneously. CLINICAL DISCUSSION: Despite its low affinity to alpha-1 adrenergic receptors, aripiprazole may be associated with priapism. Several potential factors involved in the pathogenesis of this adverse event have been reported in the literature including history of priapism in a different class of neuroleptics and consumption of psychoactive drugs which are the principal factors found in our case. CONCLUSION: Priapism may occur even during treatment with antipsychotics that have a low affinity to alpha1-adrenergic receptors. All patients on antipsychotics should be informed about the risk of this rare but serious adverse event.